ValuEngine downgraded shares of Evoke Pharma, Inc. (NASDAQ:EVOK) from a hold rating to a sell rating in a research note released on Friday morning.

A number of other research firms have also recently commented on EVOK. HC Wainwright reiterated a buy rating and set a $9.00 price objective on shares of Evoke Pharma in a research report on Tuesday, August 15th. FBR & Co reiterated a buy rating and set a $9.00 price objective on shares of Evoke Pharma in a research report on Thursday, May 18th. Finally, Zacks Investment Research cut Evoke Pharma from a hold rating to a sell rating in a research report on Thursday, August 17th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $7.25.

Shares of Evoke Pharma (NASDAQ:EVOK) traded up 3.17% on Friday, hitting $2.60. 30,689 shares of the stock traded hands. Evoke Pharma has a 12 month low of $1.35 and a 12 month high of $4.55. The firm’s 50 day moving average is $2.43 and its 200-day moving average is $2.70. The company’s market cap is $40.01 million.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.15. During the same quarter last year, the firm posted ($0.41) earnings per share. Equities analysts predict that Evoke Pharma will post ($0.88) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/evoke-pharma-inc-evok-downgraded-by-valuengine-to-sell/1538784.html.

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Evoke Pharma by 15.1% in the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after buying an additional 68,544 shares in the last quarter. Sphera Funds Management LTD. bought a new stake in Evoke Pharma during the first quarter worth approximately $1,550,000. Finally, State Treasurer State of Michigan boosted its stake in Evoke Pharma by 37.0% in the second quarter. State Treasurer State of Michigan now owns 400,000 shares of the specialty pharmaceutical company’s stock worth $1,024,000 after buying an additional 108,034 shares in the last quarter. Hedge funds and other institutional investors own 12.88% of the company’s stock.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.